P1‐238: Soluble Aβ from PSAPP mice is different to that extracted from Alzheimer patients
Warren D. Hirst(Pfizer (United States)), Jan Jacobsen(Princeton University), David Riddell(Eli Lilly (United States)), Robert A. Crozier(Pfizer (United States)), Michael M. Monaghan(Princeton University), Dominic M. Walsh(Biogen (United States)), Nathalie Breysse(Pfizer (United States)), Jeannie Chin(Baylor College of Medicine), Peter H. Reinhart(University of Massachusetts Amherst), Roland G. W. Staal, Réka Nagy(Pfizer (United States)), Menelas N. Pangalos(AstraZeneca (United Kingdom)), Amy Sung(Pfizer (United States)), Elie Needle(Pfizer (United States))
Cited by 0
Related Papers
Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease
|Neuron|2007|1.7k
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease
|Journal of Neuroscience|2011|657
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils
|Nature Chemical Biology|2011|442